Borges, VítorIsidro, JoanaCorreia, CristinaCordeiro, DoraVieira, LuísLodhia, ZohraFernandes, CândidaRodrigues, Ana MariaAzevedo, JacintaAlves, JoãoRoxo, JoãoRocha, MiguelCôrte-Real, RitaToscano, CristinaPessanha, Maria AnaNissan, IsraelPilo, ShlomoRorman, EfratDveyrin, ZeevPaitan, YossiParan, HaimWagner-Kolasko, GalBeirnes, JenniferGibbons, SuzanneSeverini, AlbertoBorrego, Maria JoséGomes, João Paulo2022-03-152022-03-152021-08-16Clin Infect Dis. 2021 Aug 16;73(4):e1004-e1007. doi: 10.1093/cid/ciab0671058-4838http://hdl.handle.net/10400.18/7991Previously, we identified a Chlamydia trachomatis Lymphogranuloma venereum (LGV) recombinant strain possessing a unique non-LGV ompA genotype. Here, culture-independent genome sequencing confirms its circulation in Europe, Middle East and North America, and unveils genetic evidence of emergence of antibiotic resistance. Multi-country and systematic molecular surveillance is needed.engChlamydia trachomatisFluoroquinolones ResistanceIntercontinental DisseminationLymphogranuloma Venereum (LGV)RecombinationInfecções Sexualmente TransmissíveisResistência aos AntimicrobianosTranscontinental dissemination of the L2b/D-Da recombinant Chlamydia trachomatis Lymphogranuloma venereum (LGV) strain: need of broad multi-country molecular surveillancejournal article10.1093/cid/ciab067